Idexx Laboratories Inc /De (IDXX) Stock Analysis and Metrics

Idexx Laboratories

NASDAQ: IDXX

$564.12 ▲ +0.55 (+0.10%)

At close: Jul 13, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap42.82 Bn

P/E39.09

P/S9.63

Div. Yield0.00

ROIC (Qtr)0.01

Total Debt (Qtr)829.85 Mn

Revenue Growth (1y) (Qtr)14.26

Add ratio to table…

About

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary, livestock, poultry and dairy, and water testing industries. The company also manufactures and sells human medical point-of-care diagnostic products. Idexx creates long-term value by enhancing the health and well-being of pets, people, and livestock through diagnostic and information management solutions.

Idexx generates revenue through the sale of point-of-care veterinary diagnostic products, veterinary reference laboratory diagnostic and consulting services, practice management systems and software, diagnostic imaging systems, health monitoring and biological materials testing products for biomedical research, diagnostic and health-monitoring products for livestock, poultry, and dairy, and water testing products. The company serves veterinarians, livestock and dairy producers, biomedical researchers, water utilities, government laboratories, and human medical facilities through direct sales, independent distributors, and resellers worldwide.

The company operates through the following segments: Companion Animal Group, Water quality products, and Livestock, Poultry and Dairy. An Other operating segment combines human medical diagnostic products and out-licensing arrangements.

• Companion Animal Group: This segment provides diagnostic and information management products and services for the companion animal veterinary industry, including point-of-care diagnostic solutions, outside reference laboratory services, and veterinary software and services. The segment includes the IDEXX VetLab suite of point-of-care chemistry, hematology, immunoassay, electrolyte, urinalysis, cytology/morphology, blood gas, and coagulation analyzers. Key products include the Catalyst One Chemistry analyzer, ProCyte One hematology analyzer, SediVue Dx Analyzer, and IDEXX inVue Dx Cellular Analyzer, which utilize proprietary AI capabilities in image capture systems.

• Water quality products: This segment provides innovative testing solutions and related instrumentation for the detection and quantification of microbiological parameters in water. Core products include the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert for enterococci, Pseudalert for Pseudomonas aeruginosa, and Legiolert for Legionella pneumophila. The segment also offers Filta-Max and Filta-Max xpress for Cryptosporidium and Giardia detection, and Quanti-Tray products for quantitative microbial measurements.

• Livestock, Poultry and Dairy: This segment provides diagnostic tests, services, and instrumentation to manage livestock and poultry health, improve producer efficiency, and measure milk quality and safety. Key products include tests for Bovine Viral Diarrhea Virus, Porcine Reproductive and Respiratory Syndrome, and Transmissible Spongiform Encephalopathies, as well as the Alertys Milk Pregnancy Test and SNAP Beta-Lactam ST and SNAPduo ST Plus for antibiotic residue detection in milk. The segment also offers herd health screening services to veterinarians and producers.

Idexx holds a strong competitive position in its core markets due to the integration of diagnostic technologies, information management systems, and a broad product portfolio. The company competes with Antech Diagnostics, Heska, Zoetis (including Abaxis), Mars, Incorporated brands, Fujifilm Holdings, Arkray, Mindray, BioNote, Neogen Corporation, Charm Sciences, BioChek, Innovative Diagnostics, Thermo Fisher Scientific, Covetrus, Sound-Eklin, and others across its various business areas. Competitive advantages include ease of use, speed, diagnostic accuracy, product quality, breadth of offerings, technological innovation, and effective sales and distribution channels.

Idexx serves veterinarians in companion animal practice, livestock and dairy producers, biomedical research laboratories, water utilities, government and private laboratories testing drinking and recreational water, and human medical facilities. The company also works with pharmaceutical and nutrition partners who use its data for market insights. Specific customer types include veterinary clinics, dairy processors, public health agencies, and research institutions.

Investment Thesis

▲ Bull case

IDEXX's strategic innovation pipeline, particularly the controlled rollout of Fecal Dx antigen testing expansion for taeniid tapeworm detection and SDMA integration into Catalyst CLIPs, represents a significant but underappreciated catalyst for recurring revenue growth that management did not heavily promote during the earnings call. The Fecal Dx expansion adds detection of clinically important parasites like Taenia and Echinococcus species, which are recognized by the Companion Animal Parasite Council as having growing relevance and zoonotic risk, particularly in endemic regions of Europe, the U.S., and Canada. This advancement builds on a platform with over 50 million tests already run worldwide since 2012, creating a scalable opportunity to increase test volume and practice adoption without additional cost to customers, thereby driving higher utilization of the existing installed base. Similarly, embedding SDMA—a biomarker recognized by the International Renal Interest Society as key for evaluating kidney function—into the most common point-of-care chemistry profiles on Catalyst addresses a critical unmet need in early chronic kidney disease detection, which is frequently unrecognized in pets. With approximately 119 million SDMA tests already performed globally, this integration leverages IDEXX's existing Catalyst installed base of nearly 79,000 customers to scale advanced kidney assessment at scale, enabling earlier intervention and stronger practice value. These innovations are not merely incremental; they expand the clinical utility of core platforms in high-frequency wellness and sick-pet care, directly supporting diagnostic frequency and utilization trends that management acknowledged as expanding at healthy rates despite flat to declining clinical visits. The market may be underestimating how these platform-enhancing innovations will drive organic recurring revenue growth through increased test panels per visit and higher customer retention, especially as IDEXX continues to bundle diagnostics into comprehensive panels like Cancer Dx, which is now used in nearly 70% of tests as part of a panel in North America. This creates a flywheel effect where innovation drives utilization, utilization strengthens customer relationships, and strong relationships fund further innovation—all of which position IDEXX to sustain double-digit growth in VetLab consumables and Reference Lab revenues beyond current guidance.
The company's international expansion strategy, particularly the localization of solutions like VetConnect PLUS and tailored product roadmaps for international markets, is creating a sustainable double-digit growth engine that is being underestimated due to macroeconomic noise and transient supply chain disruptions. Management highlighted that international CAG Diagnostics recurring revenues grew 12% organically in Q1, driven by volume gains from net new customers and same-store utilization, with steady growth attributed to ongoing customer engagement and expansion of IDEXX innovations. This performance is not merely a result of commercial execution but stems from long-term investments over the past five years in building out the full IDEXX ecosystem internationally—localizing software, tailoring solutions like ProCyte One and Rapid Assay for regional needs, and developing awareness through education and partnership models. Despite acknowledging macro pressures and supply chain dynamics impacting Water business in the Middle East, IDEXX has demonstrated the ability to out-execute these challenges through innovation and commercial partnership, as evidenced by consistent international growth even amid inflation, geopolitical instability, and currency volatility. The international opportunity is further amplified by the earlier state of diagnostics utilization in these markets, where there is significant runway for adoption as awareness builds and clinical teams integrate tools like inVue Dx into practice workflows. With customer feedback highlighting consistent performance, ease of use, and workflow productivity gains as key benefits across regions, and with early adopters of controlled launches like F&A reporting high-quality training and follow-up support, IDEXX is positioned to deepen penetration in international markets where the human-animal bond and demand for preventive care are growing. This structural shift toward globalization of advanced veterinary diagnostics is not being fully priced into the stock, as investors may be focusing too heavily on U.S. clinical visit trends while overlooking the compounding effect of international expansion on installed base growth, recurring revenue streams, and long-term margin expansion through scale.
IDEXX's capital allocation strategy, particularly the aggressive share repurchase program supported by strong free cash flow generation, is creating a powerful but underdiscussed tailwind for EPS growth that exceeds what is reflected in current guidance. The company returned $361 million to shareholders via share repurchases in Q1 alone, supporting a 2.1% year-over-year reduction in diluted shares outstanding through the quarter. This level of repurchase activity is significant relative to the company's market capitalization and demonstrates management's confidence in the durability of its cash flow generation, which achieved a trailing 12-month net income to free cash flow conversion rate of 99%. With full year capital spending maintained at approximately $180 million and free cash flow conversion outlook of 85% to 95% of net income, IDEXX has substantial excess cash flow available for continued repurchases even after funding innovation and operational investments. The reduction in share count directly amplifies EPS growth, meaning that even if operational EPS growth meets the guided 11% to 15% range, the actual reported EPS growth could be higher due to the declining denominator. This effect is compounded by the company's strong balance sheet, with leverage ratios of 0.6x gross and 0.5x net of cash, providing ample capacity to sustain or even increase repurchase pace without compromising financial flexibility. The market may be overlooking how this capital return strategy, combined with organic growth in high-margin recurring revenues from innovations like Cancer Dx and inVue Dx, creates a dual engine for shareholder value creation—where operational excellence drives cash flow, and disciplined capital allocation converts that cash flow into accretive EPS growth. This dynamic is particularly powerful in an environment where diagnostic utilization per visit is expanding, as each percentage point of recurring revenue growth translates to disproportionately higher EPS growth due to operating leverage and share count reduction.

IDEXX's strategic innovation pipeline, particularly the controlled rollout of Fecal Dx antigen testing expansion for taeniid tapeworm detection and SDMA integration into Catalyst CLIPs, represents a significant but underappreciated catalyst for recurring revenue growth that management did not heavily promote during the earnings call. The Fecal Dx expansion adds detection of clinically important parasites like Taenia and Echinococcus species, which are recognized by the Companion Animal Parasite Council as having growing relevance and zoonotic risk, particularly in endemic regions of Europe, the U.S., and Canada. This advancement builds on a platform with over 50 million tests already run worldwide since 2012, creating a scalable opportunity to increase test volume and practice adoption without additional cost to customers, thereby driving higher utilization of the existing installed base. Similarly, embedding SDMA—a biomarker recognized by the International Renal Interest Society as key for evaluating kidney function—into the most common point-of-care chemistry profiles on Catalyst addresses a critical unmet need in early chronic kidney disease detection, which is frequently unrecognized in pets. With approximately 119 million SDMA tests already performed globally, this integration leverages IDEXX's existing Catalyst installed base of nearly 79,000 customers to scale advanced kidney assessment at scale, enabling earlier intervention and stronger practice value. These innovations are not merely incremental; they expand the clinical utility of core platforms in high-frequency wellness and sick-pet care, directly supporting diagnostic frequency and utilization trends that management acknowledged as expanding at healthy rates despite flat to declining clinical visits. The market may be underestimating how these platform-enhancing innovations will drive organic recurring revenue growth through increased test panels per visit and higher customer retention, especially as IDEXX continues to bundle diagnostics into comprehensive panels like Cancer Dx, which is now used in nearly 70% of tests as part of a panel in North America. This creates a flywheel effect where innovation drives utilization, utilization strengthens customer relationships, and strong relationships fund further innovation—all of which position IDEXX to sustain double-digit growth in VetLab consumables and Reference Lab revenues beyond current guidance.
The company's international expansion strategy, particularly the localization of solutions like VetConnect PLUS and tailored product roadmaps for international markets, is creating a sustainable double-digit growth engine that is being underestimated due to macroeconomic noise and transient supply chain disruptions. Management highlighted that international CAG Diagnostics recurring revenues grew 12% organically in Q1, driven by volume gains from net new customers and same-store utilization, with steady growth attributed to ongoing customer engagement and expansion of IDEXX innovations. This performance is not merely a result of commercial execution but stems from long-term investments over the past five years in building out the full IDEXX ecosystem internationally—localizing software, tailoring solutions like ProCyte One and Rapid Assay for regional needs, and developing awareness through education and partnership models. Despite acknowledging macro pressures and supply chain dynamics impacting Water business in the Middle East, IDEXX has demonstrated the ability to out-execute these challenges through innovation and commercial partnership, as evidenced by consistent international growth even amid inflation, geopolitical instability, and currency volatility. The international opportunity is further amplified by the earlier state of diagnostics utilization in these markets, where there is significant runway for adoption as awareness builds and clinical teams integrate tools like inVue Dx into practice workflows. With customer feedback highlighting consistent performance, ease of use, and workflow productivity gains as key benefits across regions, and with early adopters of controlled launches like F&A reporting high-quality training and follow-up support, IDEXX is positioned to deepen penetration in international markets where the human-animal bond and demand for preventive care are growing. This structural shift toward globalization of advanced veterinary diagnostics is not being fully priced into the stock, as investors may be focusing too heavily on U.S. clinical visit trends while overlooking the compounding effect of international expansion on installed base growth, recurring revenue streams, and long-term margin expansion through scale.
IDEXX's capital allocation strategy, particularly the aggressive share repurchase program supported by strong free cash flow generation, is creating a powerful but underdiscussed tailwind for EPS growth that exceeds what is reflected in current guidance. The company returned $361 million to shareholders via share repurchases in Q1 alone, supporting a 2.1% year-over-year reduction in diluted shares outstanding through the quarter. This level of repurchase activity is significant relative to the company's market capitalization and demonstrates management's confidence in the durability of its cash flow generation, which achieved a trailing 12-month net income to free cash flow conversion rate of 99%. With full year capital spending maintained at approximately $180 million and free cash flow conversion outlook of 85% to 95% of net income, IDEXX has substantial excess cash flow available for continued repurchases even after funding innovation and operational investments. The reduction in share count directly amplifies EPS growth, meaning that even if operational EPS growth meets the guided 11% to 15% range, the actual reported EPS growth could be higher due to the declining denominator. This effect is compounded by the company's strong balance sheet, with leverage ratios of 0.6x gross and 0.5x net of cash, providing ample capacity to sustain or even increase repurchase pace without compromising financial flexibility. The market may be overlooking how this capital return strategy, combined with organic growth in high-margin recurring revenues from innovations like Cancer Dx and inVue Dx, creates a dual engine for shareholder value creation—where operational excellence drives cash flow, and disciplined capital allocation converts that cash flow into accretive EPS growth. This dynamic is particularly powerful in an environment where diagnostic utilization per visit is expanding, as each percentage point of recurring revenue growth translates to disproportionately higher EPS growth due to operating leverage and share count reduction.

▼ Bear case

IDEXX's reliance on premium instrument placements, particularly the inVue Dx analyzer, to drive future growth carries significant execution risk that the market may be ignoring, as placements are showing signs of pacing inconsistency and are highly dependent on customer mix and macroeconomic resilience. Although management reiterated confidence in the 5,500 annual placement target for inVue Dx, the actual Q1 placements of 1,100 units—while on track for the full year goal—reflect a quarterly run rate that would require accelerating placement momentum in subsequent quarters to meet the target, especially given the choppiness acknowledged due to customer mix between independents and corporates. The company admitted that placement trends are choppy quarter-to-quarter, and without a clear discussion of the sales funnel or conversion rates, there is uncertainty about whether the strong start in Q1 can be sustained, particularly if corporate account sales cycles lengthen or if budget constraints tighten in veterinary practices facing macroeconomic pressures. Furthermore, the inVue Dx platform's revenue contribution remains tied to the successful expansion of its menu beyond the initial ear cytology and blood morphology offerings, with the controlled rollout of Fecal Needle Aspiration (F&A) still in early stages and not yet contributing meaningfully to recurring revenue. Until F&A achieves broad adoption and the platform moves into the targeted $3,500 to $5,500 revenue per box band, the instrument's ability to drive durable consumables growth remains unproven at scale. The market may be overestimating the near-term impact of inVue Dx on VetLab consumables growth, especially given that Rapid Assay products—which include tests shifting to the Catalyst platform—were flat organically in Q1, indicating potential cannibalization or substitution effects that could offset gains from new platforms. If instrument placements fail to meet expectations or if utilization per instrument lags due to insufficient training, workflow integration, or customer hesitation around AI-dependent features, the expected recurring revenue tail from the installed base could disappoint, undermining the core growth thesis.
The company's outlook for CAG Diagnostics recurring revenue growth is increasingly dependent on offsetting structural declines in U.S. clinical visits through diagnostic frequency and utilization per visit, a strategy that may face diminishing returns as macroeconomic pressures on pet owners intensify and discretionary spending continues to be deprioritized. Management acknowledged that U.S. same-store clinical visits declined 1% in Q1 and guided to a minus 1.5% decline for the full year, with the primary driver being wellness and discretionary visits—categories that are highly sensitive to consumer economic stress. While they highlighted positive momentum from the aging pet population (5-plus years) and improved non-well visit trends, these factors may not be sufficient to counteract broader pressures if fuel prices, inflation, or economic uncertainty lead to further reductions in overall clinic traffic. The reliance on diagnostic frequency expansion as a growth lever assumes that veterinarians will continue to increase testing per visit even as visit volumes soften, but this behavior may not be sustainable if practices face financial strain or if pet owners resist additional diagnostic costs amid broader budget constraints. Moreover, the company's guidance assumes only a modest improvement in clinical visit trends from the initial outlook, implying that the bulk of growth must come from utilization gains—a risky assumption if the human-animal bond, while strong, does not translate into willingness to pay for advanced diagnostics during economic downturns. If clinical visit declines worsen beyond the guided range or if utilization per visit fails to expand at the expected pace due to practice-level economic headwinds, the organic growth outlook for CAG Diagnostics recurring revenue (8.7% to 10.7%) could prove overly optimistic, particularly given that the company explicitly stated this growth is "all volume driven" with no new pricing contributions.
IDEXX's expanding innovation agenda, while a strength, introduces rising execution complexity and potential dilution of focus across multiple platforms—including Cancer Dx, inVue Dx with its menu expansions (F&A, blood morphology, ear cytology), SDMA integration into Catalyst, and software/cloud transitions—each requiring significant commercial, training, and support resources to achieve adoption at scale. The company is simultaneously launching new products, broadening menus on existing instruments, transitioning to cloud-native software platforms, and expanding internationally, all while managing the controlled rollout of features like F&A that depend on expert pathologist review and AI analysis. This multifaceted innovation pace increases the risk of inconsistent customer experience, insufficient training coverage, or slower-than-expected adoption if veterinary practices—particularly smaller, independent clinics—are overwhelmed by the frequency of new offerings or lack the bandwidth to integrate multiple workflow changes. Management acknowledged that they are broadening the F&A launch into Q2 and planning an unconstrained launch later in the year, but until then, the platform's full value proposition remains untested at scale. Additionally, the shift to cloud-based PIMS and diagnostic imaging systems like the DR50 PLUS, while beneficial long-term, requires customers to adapt to new software ecosystems and may face resistance from practices invested in legacy systems. If the commercial team's ability to support integration, training, and follow-up is strained by the volume and complexity of innovations, customer satisfaction and retention—currently in the high 90s—could be pressured, undermining the loyalty that underpins the recurring revenue model. The market may be ignoring how the sheer pace of innovation, despite its long-term promise, could create near-term friction in adoption, increase sales and support costs, and delay the realization of expected recurring revenue growth from new platforms, particularly if the return on investment for practices is not immediately clear or if workflow disruption outweighs perceived benefits.

IDEXX's reliance on premium instrument placements, particularly the inVue Dx analyzer, to drive future growth carries significant execution risk that the market may be ignoring, as placements are showing signs of pacing inconsistency and are highly dependent on customer mix and macroeconomic resilience. Although management reiterated confidence in the 5,500 annual placement target for inVue Dx, the actual Q1 placements of 1,100 units—while on track for the full year goal—reflect a quarterly run rate that would require accelerating placement momentum in subsequent quarters to meet the target, especially given the choppiness acknowledged due to customer mix between independents and corporates. The company admitted that placement trends are choppy quarter-to-quarter, and without a clear discussion of the sales funnel or conversion rates, there is uncertainty about whether the strong start in Q1 can be sustained, particularly if corporate account sales cycles lengthen or if budget constraints tighten in veterinary practices facing macroeconomic pressures. Furthermore, the inVue Dx platform's revenue contribution remains tied to the successful expansion of its menu beyond the initial ear cytology and blood morphology offerings, with the controlled rollout of Fecal Needle Aspiration (F&A) still in early stages and not yet contributing meaningfully to recurring revenue. Until F&A achieves broad adoption and the platform moves into the targeted $3,500 to $5,500 revenue per box band, the instrument's ability to drive durable consumables growth remains unproven at scale. The market may be overestimating the near-term impact of inVue Dx on VetLab consumables growth, especially given that Rapid Assay products—which include tests shifting to the Catalyst platform—were flat organically in Q1, indicating potential cannibalization or substitution effects that could offset gains from new platforms. If instrument placements fail to meet expectations or if utilization per instrument lags due to insufficient training, workflow integration, or customer hesitation around AI-dependent features, the expected recurring revenue tail from the installed base could disappoint, undermining the core growth thesis.
The company's outlook for CAG Diagnostics recurring revenue growth is increasingly dependent on offsetting structural declines in U.S. clinical visits through diagnostic frequency and utilization per visit, a strategy that may face diminishing returns as macroeconomic pressures on pet owners intensify and discretionary spending continues to be deprioritized. Management acknowledged that U.S. same-store clinical visits declined 1% in Q1 and guided to a minus 1.5% decline for the full year, with the primary driver being wellness and discretionary visits—categories that are highly sensitive to consumer economic stress. While they highlighted positive momentum from the aging pet population (5-plus years) and improved non-well visit trends, these factors may not be sufficient to counteract broader pressures if fuel prices, inflation, or economic uncertainty lead to further reductions in overall clinic traffic. The reliance on diagnostic frequency expansion as a growth lever assumes that veterinarians will continue to increase testing per visit even as visit volumes soften, but this behavior may not be sustainable if practices face financial strain or if pet owners resist additional diagnostic costs amid broader budget constraints. Moreover, the company's guidance assumes only a modest improvement in clinical visit trends from the initial outlook, implying that the bulk of growth must come from utilization gains—a risky assumption if the human-animal bond, while strong, does not translate into willingness to pay for advanced diagnostics during economic downturns. If clinical visit declines worsen beyond the guided range or if utilization per visit fails to expand at the expected pace due to practice-level economic headwinds, the organic growth outlook for CAG Diagnostics recurring revenue (8.7% to 10.7%) could prove overly optimistic, particularly given that the company explicitly stated this growth is "all volume driven" with no new pricing contributions.
IDEXX's expanding innovation agenda, while a strength, introduces rising execution complexity and potential dilution of focus across multiple platforms—including Cancer Dx, inVue Dx with its menu expansions (F&A, blood morphology, ear cytology), SDMA integration into Catalyst, and software/cloud transitions—each requiring significant commercial, training, and support resources to achieve adoption at scale. The company is simultaneously launching new products, broadening menus on existing instruments, transitioning to cloud-native software platforms, and expanding internationally, all while managing the controlled rollout of features like F&A that depend on expert pathologist review and AI analysis. This multifaceted innovation pace increases the risk of inconsistent customer experience, insufficient training coverage, or slower-than-expected adoption if veterinary practices—particularly smaller, independent clinics—are overwhelmed by the frequency of new offerings or lack the bandwidth to integrate multiple workflow changes. Management acknowledged that they are broadening the F&A launch into Q2 and planning an unconstrained launch later in the year, but until then, the platform's full value proposition remains untested at scale. Additionally, the shift to cloud-based PIMS and diagnostic imaging systems like the DR50 PLUS, while beneficial long-term, requires customers to adapt to new software ecosystems and may face resistance from practices invested in legacy systems. If the commercial team's ability to support integration, training, and follow-up is strained by the volume and complexity of innovations, customer satisfaction and retention—currently in the high 90s—could be pressured, undermining the loyalty that underpins the recurring revenue model. The market may be ignoring how the sheer pace of innovation, despite its long-term promise, could create near-term friction in adoption, increase sales and support costs, and delay the realization of expected recurring revenue growth from new platforms, particularly if the return on investment for practices is not immediately clear or if workflow disruption outweighs perceived benefits.

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password